Steroids for acute respiratory distress syndrome?

Clinics in Chest Medicine

Volumn 35, Issue 4, 2014, Pages 781-795

  Hough, Catherine L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

ARDS; Corticosteroids; Outcomes; Prevention; Treatment

Indexed keywords

CORTICOSTEROID; GLUCOCORTICOID; STEROID;

ADULT RESPIRATORY DISTRESS SYNDROME; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DISEASE CONTROL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG RESPONSE; HIGH RISK PATIENT; HUMAN; LUNG FIBROSIS; NONHUMAN; OUTCOME ASSESSMENT; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; REVIEW; RISK ASSESSMENT; RISK FACTOR; DRUG ADMINISTRATION; RESPIRATORY DISTRESS SYNDROME, ADULT;

DRUG ADMINISTRATION SCHEDULE; GLUCOCORTICOIDS; HUMANS; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 84909633438     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2014.08.014     Document Type: Review

References (81)

1. Ashbaugh D.G., Bigelow D.B., Petty T.L., et al. Acute respiratory distress in adults. Lancet 1967, 2(7511):319-323.
2. Matthay M.A., Ware L.B., Zimmerman G.A. The acute respiratory distress syndrome. JClin Invest 2012, 122(8):2731-2740.
3. Katzenstein A.L., Bloor C.M., Liebow A.A. Diffuse alveolar damage: the role of oxygen, shock, and related factors. Am J Pathol 1976, 85:209-228.
4. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. NEngl J Med 2000, 342(18):1301-1308.
5. Ware L.B., Matthay M.A. The acute respiratory distress syndrome. NEngl J Med 2000, 342(18):1334-1349.
6. Matthay M.A., Zemans R.L. The acute respiratory distress syndrome: pathogenesis and treatment. Annu Rev Pathol 2011, 6:147-163.
7. Pittet J.F., Mackersie R.C., Martin T.R., et al. Biological markers of acute lung injury: prognostic and pathogenetic significance. Am J Respir Crit Care Med 1997, 155(4):1187-1205.
8. Barnett N., Ware L.B. Biomarkers in acute lung injury-marking forward progress. Crit Care Clin 2011, 27(3):661-683.
9. Ware L.B., Koyama T., Billheimer D.D., et al. Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest 2010, 137(2):288-296.
10. Martin C., Papazian L., Payan M.J., et al. Pulmonary fibrosis correlates with outcome in adult respiratory distress syndrome. A study in mechanically ventilated patients. Chest 1995, 107(1):196-200.
11. Clark J.G., Milberg J.A., Steinberg K.P., et al. Type III procollagen peptide in the adult respiratory distress syndrome. Association of increased peptide levels in bronchoalveolar lavage fluid with increased risk for death. Ann Intern Med 1995, 122(1):17-23.
12. Newton R. Molecular mechanisms of glucocorticoid action: what is important?. Thorax 2000, 55(7):603-613.
13. Thompson B.T. Corticosteroids for ARDS. Minerva Anestesiol 2010, 76(6):441-447.
14. Wiegers G.J., Reul J.M. Induction of cytokine receptors by glucocorticoids: functional and pathological significance. Trends Pharmacol Sci 1998, 19(8):317-321.
15. Thompson B.T. Glucocorticoids and acute lung injury. Crit Care Med 2003, 31(Suppl 4):S253-S257.
16. Wollersheim T., Woehlecke J., Krebs M., et al. Dynamics of myosin degradation in intensive care unit-acquired weakness during severe critical illness. Intensive Care Med 2014, 40:528-538.
17. Wieske L., Witteveen E., Petzold A., et al. Neurofilaments as a plasma biomarker for ICU-acquired weakness: an observational pilot study. Crit Care 2014, 18(1):R18.
18. Sharshar T., Citerio G., Andrews P.J., et al. Neurological examination of critically ill patients: a pragmatic approach. Report of an ESICM expert panel. Intensive Care Med 2014, 40:484-495.
19. Balas M.C., Vasilevskis E.E., Olsen K.M., et al. Effectiveness and safety of the awakening and breathing coordination, delirium monitoring/management, and early exercise/mobility bundle. Crit Care Med 2014, 42(5):1024-1036.
20. Argov Z., Latronico N. Neuromuscular complications in intensive care patients. Handb Clin Neurol 2014, 121:1673-1685.
21. Sibbald W.J., Anderson R.R., Reid B., et al. Alveolo-capillary permeability in human septic ARDS. Effect of high-dose corticosteroid therapy. Chest 1981, 79(2):133-142.
22. Bone R.C., Fisher C.J., Clemmer T.P., et al. Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome. Chest 1987, 92(6):1032-1036.
23. Weigelt J.A., Norcross J.F., Borman K.R., et al. Early steroid therapy for respiratory failure. Arch Surg 1985, 120(5):536-540.
24. Schein R.M., Bergman R., Marcial E.H., et al. Complement activation and corticosteroid therapy in the development of the adult respiratory distress syndrome. Chest 1987, 91(6):850-854.
25. Luce J.M., Montgomery A.B., Marks J.D., et al. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis 1988, 138(1):62-68.
26. Bone R.C., Fisher C.J., Clemmer T.P., et al. Acontrolled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. NEngl J Med 1987, 317(11):653-658.
27. Peter J.V., John P., Graham P.L., et al. Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysis. BMJ 2008, 336(7651):1006-1009.
28. Wieske L., Chan Pin Yin D.R., Verhamme C., et al. Autonomic dysfunction in ICU-acquired weakness: a prospective observational pilot study. Intensive Care Med 2013, 39(9):1610-1617.
29. Winkelman C. Mechanisms for muscle health in the critically ill patient. Crit Care Nurs Q 2013, 36(1):5-16.
30. Bernard G.R., Luce J.M., Sprung C.L., et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. NEngl J Med 1987, 317(25):1565-1570.
31. Annane D., Sebille V., Charpentier C., et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002, 288(7):862-871.
32. Marik P.E., Pastores S.M., Annane D., et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 2008, 36(6):1937-1949.
33. Bernard G.R., Artigas A., Brigham K.L., et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994, 149(3 Pt 1):818-824.
34. Annane D., Sebille V., Bellissant E., Ger-Inf-05 Study Group Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome. Crit Care Med 2006, 34(1):22-30.
35. Sprung C.L., Annane D., Keh D., et al. Hydrocortisone therapy for patients with septic shock. NEngl J Med 2008, 358(2):111-124.
36. Meduri G.U., Golden E., Freire A.X., et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest 2007, 131(4):954-963.
37. Murray J.F., Matthay M.A., Luce J.M., et al. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 1988, 138(3):720-723.
38. Schoenfeld D.A., Bernard G.R. Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med 2002, 30(8):1772-1777.
39. Confalonieri M., Urbino R., Potena A., et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005, 171(3):242-248.
40. Trees D.W., Smith J.M., Hockert S. Innovative mobility strategies for the patient with intensive care unit-acquired weakness: a case report. Phys Ther 2013, 93(2):237-247.
41. Meduri G.U., Belenchia J.M., Estes R.J., et al. Fibroproliferative phase of ARDS. Clinical findings and effects of corticosteroids. Chest 1991, 100(4):943-952.
42. Meduri G.U., Chinn A.J., Leeper K.V., et al. Corticosteroid rescue treatment of progressive fibroproliferation in late ARDS. Patterns of response and predictors of outcome. Chest 1994, 105(5):1516-1527.
43. Meduri G.U. Pulmonary fibroproliferation and death in patients with late ARDS. Chest 1995, 107(1):5-6.
44. Hooper R.G., Kearl R.A. Established adult respiratory distress syndrome successfully treated with corticosteroids. South Med J 1996, 89(4):359-364.
45. Ashbaugh D.G., Maier R.V. Idiopathic pulmonary fibrosis in adult respiratory distress syndrome. Diagnosis and treatment. Arch Surg 1985, 120(5):530-535.
46. Meduri G.U., Headley A.S., Golden E., et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA 1998, 280(2):159-165.
47. Steinberg K.P., Hudson L.D., Goodman R.B., et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. NEngl J Med 2006, 354(16):1671-1684.
48. Meduri G.U., Marik P.E., Chrousos G.P., et al. Steroid treatment in ARDS: a critical appraisal of the ARDS network trial and the recent literature. Intensive Care Med 2008, 34(1):61-69.
49. Hough C.L., Steinberg K.P., Taylor Thompson B., et al. Intensive care unit-acquired neuromyopathy and corticosteroids in survivors of persistent ARDS. Intensive Care Med 2009, 35(1):63-68.
50. Stevens R.D., Dowdy D.W., Michaels R.K., et al. Neuromuscular dysfunction acquired in critical illness: a systematic review. Intensive Care Med 2007, 33(11):1876-1891.
51. Semmler A., Okulla T., Kaiser M., et al. Long-term neuromuscular sequelae of critical illness. JNeurol 2013, 260(1):151-157.
52. Hermans G., Wilmer A., Meersseman W., et al. Impact of intensive insulin therapy on neuromuscular complications and ventilator dependency in the medical intensive care unit. Am J Respir Crit Care Med 2007, 175(5):480-489.
53. Hudson L.D., Hough C.L. Therapy for late-phase acute respiratory distress syndrome. Clin Chest Med 2006, 27(4):671-677. [abstract: ix-x].
54. De Jonghe B., Sharshar T., Lefaucheur J.P., et al. Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA 2002, 288(22):2859-2867.
55. Herridge M.S., Cheung A.M., Tansey C.M., et al. One-year outcomes in survivors of the acute respiratory distress syndrome. NEngl J Med 2003, 348(8):683-693.
56. Davydow D.S., Kohen R., Hough C.L., et al. Apilot investigation of the association of genetic polymorphisms regulating corticotrophin-releasing hormone with posttraumatic stress and depressive symptoms in medical-surgical intensive care unit survivors. JCrit Care 2014, 29(1):101-106.
57. Schelling G., Stoll C., Kapfhammer H.P., et al. The effect of stress doses of hydrocortisone during septic shock on posttraumatic stress disorder and health-related quality of life in survivors. Crit Care Med 1999, 27(12):2678-2683.
58. Iwashyna T.J., Angus D.C. Declining case fatality rates for severe sepsis: good data bring good news with ambiguous implications. JAMA 2014, 311:1295-1297.
59. Ranieri V.M., Suter P.M., Tortorella C., et al. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. JAMA 1999, 282(1):54-61.
60. Cabrera-Benitez N.E., Parotto M., Post M., et al. Mechanical stress induces lung fibrosis by epithelial-mesenchymal transition. Crit Care Med 2012, 40(2):510-517.
61. Tremblay L., Valenza F., Ribeiro S.P., et al. Injurious ventilatory strategies increase cytokines and c-fos m-RNA expression in an isolated rat lung model. JClin Invest 1997, 99(5):944-952.
62. Ricard J.D., Dreyfuss D., Saumon G. Production of inflammatory cytokines in ventilator-induced lung injury: a reappraisal. Am J Respir Crit Care Med 2001, 163(5):1176-1180.
63. Nalayanda D.D., Fulton W.B., Colombani P.M., et al. Pressure induced lung injury in a novel invitro model of the alveolar interface: protective effect of dexamethasone. JPediatr Surg 2014, 49(1):61-65. [discussion: 65].
64. Hegeman M.A., Hennus M.P., Cobelens P.M., et al. Dexamethasone attenuates VEGF expression and inflammation but not barrier dysfunction in a murine model of ventilator-induced lung injury. PLoS One 2013, 8(2):e57374.
65. Hegeman M.A., Cobelens P.M., Kamps J., et al. Liposome-encapsulated dexamethasone attenuates ventilator-induced lung inflammation. Br J Pharmacol 2011, 163(5):1048-1058.
66. Agarwal R., Nath A., Aggarwal A.N., et al. Do glucocorticoids decrease mortality in acute respiratory distress syndrome? A meta-analysis. Respirology 2007, 12(4):585-590.
67. Lamontagne F., Briel M., Guyatt G.H., et al. Corticosteroid therapy for acute lung injury, acute respiratory distress syndrome, and severe pneumonia: a meta-analysis of randomized controlled trials. JCrit Care 2010, 25(3):420-435.
68. Tang B.M., Craig J.C., Eslick G.D., et al. Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis. Crit Care Med 2009, 37(5):1594-1603.
69. Lee H.S., Lee J.M., Kim M.S., et al. Low-dose steroid therapy at an early phase of postoperative acute respiratory distress syndrome. Ann Thorac Surg 2005, 79(2):405-410.
70. Keel J.B., Hauser M., Stocker R., et al. Established acute respiratory distress syndrome: benefit of corticosteroid rescue therapy. Respiration 1998, 65(4):258-264.
71. Varpula T., Pettila V., Rintala E., et al. Late steroid therapy in primary acute lung injury. Intensive Care Med 2000, 26:526-531.
72. Huh J., Lim C.M., Jegal Y. The effect of steroid therapy in patients with late ARDS. Tuberc Respir Dis (Seoul) 2002, 52:376-384.
73. Gagnon S., Boota A.M., Fischl M.A., et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a double-blind, placebo-controlled trial. NEngl J Med 1990, 323(21):1444-1450.
74. Kovacs J.A., Masur H. Are corticosteroids beneficial as adjunctive therapy for Pneumocystis pneumonia in AIDS?. Ann Intern Med 1990, 113(1):1-3.
75. Montaner J.S., Lawson L.M., Levitt N., et al. Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990, 113(1):14-20.
76. Azoulay E., Canet E., Raffoux E., et al. Dexamethasone in patients with acute lung injury from acute monocytic leukaemia. Eur Respir J 2012, 39(3):648-653.
77. Cronin L., Cook D.J., Carlet J., et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995, 23(8):1430-1439.
78. Nie W., Zhang Y., Cheng J., et al. Corticosteroids in the treatment of community-acquired pneumonia in adults: a meta-analysis. PLoS One 2012, 7(10):e47926.
79. Brun-Buisson C., Richard J.C., Mercat A., REVA-SRLF A/H1N1v 2009 Registry Group, et al. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med 2011, 183(9):1200-1206.
80. Kim S.H., Hong S.B., Yun S.C., et al. Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am J Respir Crit Care Med 2011, 183(9):1207-1214.
81. Martin-Loeches I., Lisboa T., Rhodes A., et al. Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection. Intensive Care Med 2011, 37(2):272-283.